ReviewProtein & cell2021
The role of the gut microbiome and its metabolites in metabolic diseases.
Review in Protein & cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07124585 (Short-Term Effect of Non-Nutritive Sweeteners), which is not on this map. Cited by 313 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Short-Term Effect of Non-Nutritive Sweeteners (Sucralose and Saccharin) Consumption on Glycaemic Control and Gut Microbiota in Type 2 Diabetes Patients
Who cites it
313 citing papers in PubMed, 2 syntheses or guidelines pooled it, 513 citations in OpenAlex.
- The role of microbiota derived metabolites in modulating diabetic inflammation: a systematic review.Journal of molecular histology · 2026Pooled it
- Pharmacological Mechanisms of Bile Acids Targeting the Farnesoid X Receptor.International journal of molecular sciences · 2024Pooled it
- Trial
- Cholesterol-lowering effects of oats induced by microbially produced phenolic metabolites in metabolic syndrome: a randomized controlled trial.Nature communications · 2026Trial
- Effect of AG1Frontiers in nutrition · 2026Trial
- Sex differences in the gut microbiome and related metabolites: role in cardiometabolic disease.Gut microbes · 2026Review
- Gut microbiota metabolic reprogramming drives the development of metabolic diseases in the host.Gut microbes · 2026Review
- Gut Microbiota-Derived Extracellular Vesicles in Cancer: Friends or Foes?Probiotics and antimicrobial proteins · 2026Review
- Gut Microbiome and Fecal Metabolome Analysis Reveal Potential Non-Invasive Biomarkers For Acute Myocardial Infarction.Probiotics and antimicrobial proteins · 2026Article
- ROS/pH-Responsive Phenylboronic Acid-Chitosan Nanoparticles Improve Silymarin-Mediated Hepatoprotection After Hepatectomy With Gut-Liver Axis-Associated Responses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Natural product therapy in diabetic kidney disease: emerging multiomics-mediated signalling pathway and molecular target.Chinese medicine · 2026Review
- Gut microbiota contributes to the therapeutic effect of acupuncture in atopic dermatitis.Microbiology spectrum · 2026Article
- Revolutionizing neonatal health: India's journey from assays to advanced genetics.Journal of applied genetics · 2026Review
- Targeting the human gut microbiome: a comparative review of probiotics, prebiotics, synbiotics, and postbiotics.Journal of advanced research · 2026Review
- Despite Its High Salt Content,Food science & nutrition · 2026Article
- Porcine intestinal goblet cells: Guardians of mucosal immunity and barrier function.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Review
- Effects of Growth Stage and Physiological State on Gut Health, Antioxidant Capacity, and Muscle Nutritional Composition in Greenhouse-CulturedAntioxidants (Basel, Switzerland) · 2026Article
- Safety and Effectiveness of Probiotic Preparations: A Contemporary Review.Diseases (Basel, Switzerland) · 2026Review
- Bioactive compounds of Glycyrrhiza glabra and their functional role in modulating gut inflammation and intestinal homeostasis.Inflammopharmacology · 2026Review
- Resistant starch as a dietary strategy for metabolic and gut health: Implications for Asia-Pacific populations.Asia Pacific journal of clinical nutrition · 2026Review
253 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well known that an unhealthy lifestyle is a major risk factor for metabolic diseases, while in recent years, accumulating evidence has demonstrated that the gut microbiome and its metabolites also play a crucial role in the onset and development of many metabolic diseases, including obesity, type 2 diabetes, nonalcoholic fatty liver disease, cardiovascular disease and so on. Numerous microorganisms dwell in the gastrointestinal tract, which is a key interface for energy acquisition and can metabolize dietary nutrients into many bioactive substances, thus acting as a link between the gut microbiome and its host. The gut microbiome is shaped by host genetics, immune responses and dietary factors. The metabolic and immune potential of the gut microbiome determines its significance in host health and diseases. Therefore, targeting the gut microbiome and relevant metabolic pathways would be effective therapeutic treatments for many metabolic diseases in the near future. This review will summarize information about the role of the gut microbiome in organism metabolism and the relationship between gut microbiome-derived metabolites and the pathogenesis of many metabolic diseases. Furthermore, recent advances in improving metabolic diseases by regulating the gut microbiome will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.